Source: U.S. News & World Report
Quanterix showcases its Edison Award-winning PhenoCode Discovery™ IO60 Human Protein Panel as a new standard for spatial biology, delivering a comprehensive view of the tumor immune environment through 60 biomarkers analyzed simultaneously.
As Ritu Mihani, Director of Spatial Portfolio Strategy, Quanterix explains, the long-term vision is personalized biomarker signatures that help predict how an individual’s cancer will respond to treatment, connecting insights across blood and tissue beyond what traditional diagnostics can provide.
Read the full article in U.S. News & World Report: Snapshots of Health Innovation From the Edison Awards | U.S. News Live | U.S. News
Related Posts
Building the Tools Parkinson’s Disease Research Needs
A Q&A with Kishore Malyavantham, PhD, VP of R&D at Quanterix and Co-Investigator, PD-BUILD Quanterix has been named a Co-Investigator institution in PD-BUILD (Biomarker Utilization, Innovation, and Laboratory-to-Deployment), a new project…
Quanterix Named to ASAP CRN 2026 PD-BUILD Program with MJFF Support
Part of a global effort to advance Parkinson’s disease biomarkers through standardized, scalable assay development Quanterix has been selected as a Co-Investigator institution in the PD-BUILD program, part of the…
Neurology
Why biomarkers are no longer supplemental
Quanterix makes the case with ctDNA in oncology, p-tau217 in Alzheimer’s and a lab model built for longitudinal, regulatory-grade data. Biomarkers have moved from “nice-to-have” to the backbone of drug…
Neurology
Preparing The Market for Blood-Based Biomarkers
Shana Tetrault, PhD, Director of Product Marketing at Quanterix, outlined strategies for integrating blood-based biomarkers into routine clinical care pathways, ensuring minimal disruption for patients and clinicians. Watch the full…
Neurology
Challenges of Positioning an Ultra-Sensitive Platform
Shana Tetrault, PhD, Director of Product Marketing at Quanterix, discussed challenges in positioning Simoa in the precision health market, stressing its accuracy and reliability in diverse populations. Watch the full…
Neurology
Translating Complex Scientific Findings into Actionable Insights
Shana Tetrault, PhD, Director of Product Marketing at Quanterix, discussed translating complex scientific findings into actionable insights for healthcare providers and stakeholders, emphasizing the importance of early disease detection. Watch…
Neurology
AI and the rise of blood-based biomarkers heralds new era for neurological diagnostics
Advances in blood-based biomarkers are transforming early and accurate Alzheimer’s disease detection, offering less invasive, cost-effective alternatives to traditional diagnostic methods. Quanterix, a company working at the very frontiers of…
Neurology
Quanterix Wins 2025 R&D 100 Award for Simoa BD-Tau Advantage PLUS Assay
Quanterix has been named a winner of the 2025 R&D 100 Awards in the Analytical/Test category for the Simoa® BD-Tau Advantage PLUS Assay. These prestigious awards, often referred to as…